The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
Open accessAbstract
Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%). Deletions involving chromosome 6q are common in patients with mutated MYD88 and include genes that modulate NFKB, BCL2, Bruton tyrosine kinase (BTK), and apoptosis. Patients with wild-type MYD88 WM show an increased risk of transformation and death and exhibit many mutations found in diffuse large B-cell lymphoma. The discovery of MYD88 and CXCR4 mutations in WM has facilitated rational drug development, including the development of BTK and CXCR4 inhibitors. Responses to many agents commonly used to treat WM, including the BTK inhibitor ibrutinib, are affected by MYD88 and/or CXCR4 mutation status. The mutation status of both MYD88 and CXCR4 can be used for a precision-guided treatment approach to WM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111 · cited 1×
“Dimerization of MYD88 provides a scaffold for recruitment of other proteins to a Myddosome complex that triggers downstream signaling, leading to nuclear factor-kB (NFKB) activation (Fig 1).(29) Both IRAK1/ IRAK4 and BTK are Myddosome components and trigger NFKB.”
BackgroundHernandez, P. A., Gorlin, R. J., Lukens, J. N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M. E., & Diaz, G. A. (2003) · Nature Genetics · doi:10.1038/ng1149 · Cited by 722 · cited 1×
“Germline mutations in the C-terminal domain of CXCR4 are present in patients with WHIM (autosomal dominant warts, hypogammaglobulinemia, infection, and myelokathexis) syndrome.(40) In patients with WHIM syndrome, activation of CXCR4 by its ligand CXCL12 induces extended chemotactic signaling and neutrophil sequestrati…”
BackgroundHCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Yang, G., Buhrlage, S. J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J. G., Patterson, C. J., Brown, J. R., et al. (2016) · Blood · doi:10.1182/blood-2016-01-695098 · Cited by 135 · cited 7×
“Both BTK and HCK are targets of ibrutinib, which has shown remarkable activity in patients with mutated MYD88 WM.32,33 More recently, a role for mutated MYD88 as a trigger for B-cell receptor (BCR) pathway cross talk has been proposed.”
BackgroundSelf-citation
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Metadata
- Authors
- Treon, S. P., Xu, L., Guerrera, M. L., Jimenez, C., Hunter, Z. R., Liu, X., Demos, M., Gustine, J., Chan, G., Munshi, M., Tsakmaklis, N., Chen, J. G., Kofides, A., Sklavenitis-Pistofidis, R., Bustoros, M., Keezer, A., Meid, K., Patterson, C. J., Sacco, A., Roccaro, A., Branagan, A. R., Yang, G., Ghobrial, I. M., & Castillo, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-04-10
- Volume
- 38
- Issue
- 11
- Pages
- 1198-1208
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3008151606
- Cited by
- 165
- References
- 3
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.